Search results: Sage Journals

Restricted accessResearch articleFirst published August, 2024

Does enzalutamide related PSMA upregulation affect outcomes of lutetium-177 PSMA radioligand therapy?

Turgut Bora Cengiz, Raksha Kulkarni, Matteo Novello [...]

Urologia Journal

Open accessReview articleFirst published 2023

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials

Albert Jang, Ayse T. Kendi, Oliver Sartor

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2020

PSMA PET/CT Identifies Intrapatient Variation in Salivary Gland Toxicity From Iodine-131 Therapy

Vineet Mohan, Wouter V. Vogel, Gerlof D. Valk [...]

Molecular Imaging

Open accessCase reportFirst published 2023

Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review

Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson [...]

Therapeutic Advances in Medical Oncology

Open accessReview articleFirst published 2018

PSMA Theranostics: Current Status and Future Directions

Kambiz Rahbar, Ali Afshar-Oromieh, Hossein Jadvar [...]

Molecular Imaging

Open accessReview articleFirst published 2019

Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?

Ramin Alipour, Arun Azad, Michael S. Hofman

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published 2026

Precision Oncology with 177 Lu-PSMA-617 Radionuclide Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer

Fayou Zhou, Yongqing Zheng, Liang Huang [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessReview articleFirst published August, 2022

Update on radioligand therapy with 177 Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects

Valentina Fuoco, Giovanni Argiroffi, Stefania Mazzaglia [...]

Tumori Journal

Open accessReview articleFirst published 2021

PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?

Anne-Laure Giraudet, David Kryza, Michael Hofman [...]

Therapeutic Advances in Medical Oncology

Open accessReview articleFirst published 2022

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review

Isabel Heidegger, Claudia Kesch, Alexander Kretschmer [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published August, 2024

Does enzalutamide related PSMA upregulation affect outcomes of lutetium-177 PSMA radioligand therapy?

Turgut Bora Cengiz, Raksha Kulkarni, Matteo Novello [...]

Urologia Journal

Open accessReview articleFirst published 2023

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials

Albert Jang, Ayse T. Kendi, Oliver Sartor

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2020

PSMA PET/CT Identifies Intrapatient Variation in Salivary Gland Toxicity From Iodine-131 Therapy

Vineet Mohan, Wouter V. Vogel, Gerlof D. Valk [...]

Molecular Imaging

Open accessCase reportFirst published 2023

Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review

Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson [...]

Therapeutic Advances in Medical Oncology

Open accessReview articleFirst published 2018

PSMA Theranostics: Current Status and Future Directions

Kambiz Rahbar, Ali Afshar-Oromieh, Hossein Jadvar [...]

Molecular Imaging

Open accessReview articleFirst published 2019

Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?

Ramin Alipour, Arun Azad, Michael S. Hofman

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published 2026

Precision Oncology with 177 Lu-PSMA-617 Radionuclide Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer

Fayou Zhou, Yongqing Zheng, Liang Huang [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessReview articleFirst published August, 2022

Update on radioligand therapy with 177 Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects

Valentina Fuoco, Giovanni Argiroffi, Stefania Mazzaglia [...]

Tumori Journal

Open accessReview articleFirst published 2021

PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?

Anne-Laure Giraudet, David Kryza, Michael Hofman [...]

Therapeutic Advances in Medical Oncology

Open accessReview articleFirst published 2022

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review

Isabel Heidegger, Claudia Kesch, Alexander Kretschmer [...]

Therapeutic Advances in Medical Oncology